2025 has been a productive year in gut microbiome research, spanning metabolic health, neurogastroenterology, immune modulation, and precision nutrition. In this ‘Year in Review’ article, the GMFH editing team describes their pick of the top GMFH-covered advances in 2025, outlining their impact in the clinical setting and implications for current and future research.
Imidazole propionate: a novel driver of atherosclerosis and biomarker of subclinical disease
4 Dec 2025by Andreu Prados
Cardiovascular diseases remain one of the most pressing public health concerns, demanding innovative research to identify novel causes. A recent Nature study reported that imidazole propionate made by gut bacteria contributes to atherosclerosis development, supporting its potential role as a biomarker of subclinical disease.
Fecal microbiota transplantation unable to induce remission at 8 weeks in adults with Crohn’s disease
17 Nov 2025by Karen Madsen
Previous clinical studies have shown a promising role of fecal microbiota transplantation to induce remission in ulcerative colitis and maintain steroid-induced Crohn’s disease remission. A new double-blind, placebo-controlled trial found fecal microbiota transplantation is not effective at inducing clinical or endoscopic remission in adults with Crohn’s disease.
The 6th biennial meeting of the European Society of Neurogastroenterology and Motility, held at Queen Mary University of London, UK, from 4-6 September 2025, covered basic, translational, and clinical research in neurogastroenterology, including dietary therapies and ‘biotics’ for the management of gastrointestinal disorders. Find out more about the main takeaways from the conference.
Precision therapy in Crohn’s disease: Why the microbiome should be part of the equation
25 Aug 2025by Konstantina Zafeiropoulou
Crohn’s disease is an immune-mediated disease without a cure. While current guideline-based therapies are immune-directed therapies (small molecules and biologics), recent advances in understanding how the gut microbiome changes precede and drive disease offer potential for developing personalized therapeutics.
Emerging research suggests a complex interaction between the gut microbiome and endometriosis. Recent studies have begun to explore the impact of dietary interventions on endometriosis.
Clinical translation of microbiome research: takeaways from the 2025 GMFH Summit
16 May 2025by Andreu Prados
The 13th Gut Microbiota for Health World Summit took place 15-16 March 2025 in Washington, D.C., and it focused on advances in microbiome research to diagnose, prevent, and manage gastrointestinal and extra-intestinal conditions. Find out more about the most valuable takeaways from the event.
Scientists uncover a new way by which gut microbes control cholesterol levels
24 Feb 2025by Mónica Quinzo
Gut microbiota aids in fat digestion by converting primary bile acids into unconjugated and secondary bile acids. Recent research in mice has uncovered an intricate host-microbiota partnership in regulating bile acid production, helping to prevent excessive accumulation and maintain metabolic balance.
Unlocking the diagnostic and therapeutic potential roles of gut microbiome: takeaways from the 2024 GMFH Summit
23 May 2024by Joël Doré, Andreu Prados
The last 12th Gut Microbiota for Health World Summit took place 23-24 March 2024 in Washington, D.C. and focused on relevant gut microbiome advances from the lab to the clinic. Find out more about the main takeaways of the conference and how they might affect your research and practice.
Dysosmobacter welbionis as potential promising next-generation probiotic for improving metabolic health?
8 May 2024by Patrice D. Cani
Dysosmobacter welbionis is a typical inhabitant of the human gut. New findings suggest it could be a potential next-generation beneficial bacterium for tackling specific cardiometabolic disorders linked to obesity and type 2 diabetes.
